An analysis from the FLEX study showed that only patients in MammaPrint's highest risk category benefitted from the addition ...
The company is trying again after receiving a complete response letter from the FDA last year requested more data.
Geopolitical tensions with the US and the allure of cheaper and quicker trials are drawing Chinese biotechs developing ...
The firm's newly launched Cas-CLEAR platform uses Cas12a2 nucleases to recognize and kill cancer cells expressing certain genetic signatures.
The drugmaker made its decision after reviewing clinical and non-clinical studies, and said it's committed to exploring other treatment approaches.
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
Current Chemolab equity holders will own approximately 32 percent of the combined company' shares and Scipher equity holders will own 68 percent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results